Table 3.
Patient | Duration of infection prior to treatment | Induction | Consolidation | ||
---|---|---|---|---|---|
Treatment | Duration | Treatment | Duration | ||
Successful eradication | |||||
16 (Corral, 2008) [10] | Unknown – lived in BVI | Meropenem 2 g tds | 19 days | TMP/SMX 960 mg bd | 19 days |
Minocycline 100 mg bd | |||||
Minocycline 100 mg bd | |||||
Tobramycin (neb)a 80 mg bd | |||||
20 (O’Sullivan, 2011) [13] | 3 months | Imipenem | 14 days | Meropenem (neb) | 28 days |
Ceftazidime | TMP/SMX 960 mg bd | 2 years | |||
4 (Visca, 2001) [15] | 12 months | Ceftazidime | 42 days | TMP/SMX 960 mg bd | 210 days |
TMP/SMX 960 mg bd | Doxycycline | ||||
Chloramphenicol | |||||
13 (Asiah, 2006) [8] | 12 months | Ceftazidime | 56 days | TMP/SMX 960 mg bd | 112 days |
TMP/SMX 960 mg bd | Doxycycline | ||||
22 (Radhakrishna, 2014) [17] | 7 years | Meropenem 2 g tds | Approx 56 days | Doxycycline followed by amoxycillin/clavulanic acid (doxycycline allergy) | 12 months |
Ceftazidime 3 g tds | |||||
Tobramycin (neb) 80 mg bd | |||||
TMP/SMX 960 mg bd | |||||
9 (Holland, 2002) [16] Infection 1 | Unknown | Ceftazidime | 14 days | TMP/SMX 960 mg bd | 90 days |
TMP/SMX 960 mg bd | |||||
9 (Holland, 2002) [16] Infection 2 | 1 month | Ceftazidime | 21 days | TMP/SMX 960 mg bd | 90 days |
TMP/SMX 960 mg bd | |||||
9 (Holland, 2002) [16] Infection 3 | 1-2 months | Ceftazidime | 14 days | TMP/SMX 960 mg bd | 90 days |
TMP/SMX 960 mg bd | |||||
Failed Eradication | |||||
8 (O’Carroll, 2003) [12] | 4 months | Meropenem 2 g tds | 56 days | None | |
Ceftazidime 3 g tds | |||||
17 | 6-12 months | Ceftazidime 3 g tds | 14 days | TMP/SMX 960 mg bd | 84 days |
TMP/SMX 960 mg bd | |||||
23 | >10 months | Ceftazidime 3 g tds | 21 days | Unknown (patient moved to Malaysia) | |
TMP/SMX 960 mg bd | |||||
Tobramycin 5 mg/kg | |||||
3 (Schülin, 2001) [14] | 6 years | Unspecified antipseudomonal antibiotics | 14 days | No (exacerbations directed against PsA) | |
14 (Barth, 2007) [9] | >18 months | Pipracillin/clavulanate | 21 days | Meropenem 2 g tds | 21 days |
Tobramycin 5 mg/kg | Ceftazidime 3 g tds | ||||
Amikacin | |||||
TMP/SMX 960 mg bd | |||||
15 | >8 years | Meropenem 2 g tds | 14 days | TMP/SMX 960 mg bd | 126 days |
Tobramycin | Minocycline 100 mg bd | ||||
Meropenem (neb) | |||||
18 (1st attempt) | 2 months | Ceftazidime 1.5 g tds | 14 days | Infection not cleared therefore 2nd course of IV antibiotics | |
Tobramycin 300 mg | |||||
Amoxycillin/Clavulanic acid 900 mg | |||||
18 (2nd attempt) | 2 months | Meropenem | 84 days | TMP/SMX 960 mg bd | Long term |
Ceftazidime | Doxycycline | ||||
Amoxycillin/Clavulanic acid | |||||
6 (Holland, 2002) [16] | >4 years | Ceftazidime 50 mg/kg | 120 days | None (exacerbations directed against B. pseudomallei) | |
Piperacillin 50 mg/kg | |||||
Amoxycillin/Clavulanic acid | |||||
7 (Holland, 2002) [16] | >5 years | TMP/SMX 960 mg bd | 4 years | ||
1st isolation | |||||
7 (Holland, 2002) [16] | >9 years | Imipenem | 20 days | TMP/SMX 960 mg bd | 19 days |
2nd isolation | Piperacillin/Clavulanic acid | 42 days | Tetracycline | 30 days | |
Meropenem/TMP/SMX | >30 days | ||||
11 (Holland, 2002) [16] | 3 months | Ceftazidime | 14 days | TMP/SMX 960 mg bd | 330 days |
Tobramycin | |||||
21 | 1 month | Meropenem 2 g tds | 42 days | Tobramycin (neb) 300 mg bd | 42 days |
Ceftazidime 3 g tds | TMP/SMX 960 mg bd | ||||
Tobramycin 7 mg/kg |
Success of eradication for patient 24 and patient 25 unknown
aneb = nebulized